ArticleAnnals of translational medicine2019
Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea.
Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Mechanisms underlying end-organ injury in sleep apnoea.The European respiratory journal · 2026Review
- Restoring Physiological Normoxia as an Adjuvant Strategy to Improve Cancer Treatment Outcomes.Nature and science of sleep · 2026Review
- Obstructive sleep apnea and lung cancer: molecular underpinnings and clinical translational prospects.Frontiers in cell and developmental biology · 2026Review
- Obstructive sleep apnea as a modifier of endocrine toxicities associated with immune checkpoint inhibitors in lung cancer.Frontiers in immunology · 2026Review
- Advances in immunology of obstructive sleep apnea: mechanistic insights, clinical impact, and therapeutic perspectives.Frontiers in immunology · 2025Review
- Intermittent hypoxia induces hepatic senescence through promoting oxidative stress in a mouse model.Sleep & breathing = Schlaf & Atmung · 2024Article
- Article
- A review of obstructive sleep apnea and lung cancer: epidemiology, pathogenesis, and therapeutic options.Frontiers in immunology · 2024Review
- International Consensus Statement on Obstructive Sleep Apnea.International forum of allergy & rhinology · 2023Review
- Extracellular vesicles derived from lung cancer cells exposed to intermittent hypoxia upregulate programmed death ligand 1 expression in macrophages.Sleep & breathing = Schlaf & Atmung · 2022Article
- The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury.Cell communication and signaling : CCS · 2021Review
- Review
- Intermittent hypoxia induces tumor immune escape in murine S180 solid tumors via the upregulation of TGF-βSleep & breathing = Schlaf & Atmung · 2021Article
- Hypoxia, oxidative stress, and immune evasion: a trinity of the trichothecenes T-2 toxin and deoxynivalenol (DON).Archives of toxicology · 2021Review
- Sleep Apnoea Adverse Effects on Cancer: True, False, or Too Many Confounders?International journal of molecular sciences · 2020Review
- The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer.Current genomics · 2020Review
- Differential expression of microRNAs in xenografted Lewis lung carcinomas subjected to intermittent hypoxia: a next-generation sequence analysis.Translational cancer research · 2020Article
- Acute vs. Chronic vs. Cyclic Hypoxia: Their Differential Dynamics, Molecular Mechanisms, and Effects on Tumor Progression.Biomolecules · 2019Review
- Sodium Tanshinone IIA Sulfonate Attenuates Tumor Oxidative Stress and Promotes Apoptosis in an Intermittent Hypoxia Mouse Model.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a hallmark of obstructive sleep apnea (OSA), intermittent hypoxia (IH) promotes tumor progress. The high expression of programmed death 1 and programmed death ligand 1 (PD-L1) in tumor leads to immune evasion and subsequently aggravates tumor progress. This study aims to determine the tumor PD-L1 expression under the IH condition.
methodsA total of 24 C57BL/6J mice were randomly assigned to the normoxia (control, CTL) group and the IH group. Mice in the IH group were subjected to the IH condition for 5 weeks. Lung cancer cells were injected into the flank of each mouse after 1 week of IH exposure. Tumor PD-L1 expression was detected by immunohistochemistry (IHC). Correlation between tumor weight, tumor volume, and expression of PD-L1 was analyzed.
resultsCompared to the CTL group, mice in the IH group had a high PD-L1 expression. The IH can enhance the tumor PD-L1 expression. Tumor weight, volume, and HIF-1α levels were closely associated with the PD-L1 expression in the IH group, while dissimilar findings were observed in the CTL group.
conclusionsThe IH enhances tumor PD-L1 expression in OSA mimicking mice. Additional studies are required to clarify the underlying mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.